Transdermal Buprenorphine Patches for Postoperative Pain Control in Abdominal Surgery

Kumar, Santosh

doi:10.7860/jcdr/2016/18152.7982

Cited by 13 publications

(30 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Efficacy and tolerability of TDB patch for post-operative pain control in abdominal surgery and in the treatment of chronic pain have been well established in previous studies. [ 22 23 24 ]…”

Section: Discussionmentioning

confidence: 99%

Efficacy of transdermal buprenorphine patch on post-operative pain relief after elective spinal instrumentation surgery

et al. 2017

View full text Add to dashboard Cite

Background and Aims:Transdermal buprenorphine patch (TDB) is increasingly used for chronic pain management because of non-invasive dosing, longer duration of action and minimal side effects. However its role in acute post-operative pain management for spinal instrumentation surgery is not well established. The aim of this study was to evaluate the analgesic efficacy of buprenorphine patch for postoperative pain relief in patients undergoing spinal instrumentation surgery.Methods:In this randomised, placebo-controlled, double-blinded, prospective study, 70 adult patients undergoing elective spinal instrumentation surgery were randomly allocated into two groups-TDB Group (buprenorphinepatch) and TDP Group (placebo patch). Time to first rescue analgesic requirement was the primary outcome. All patients also were monitored for total rescue analgesic requirement, drug-related adverse effect and haemodynamic status till 48 h after surgery. Statistical analysis was carried out using student independent t-test if normally distributed or with Mann–Whitney U-test if otherwise.Results:Time to first post-operative rescue analgesic (tramadol) requirement was much delayed in TDB Group than TDP Group (708.0 ± 6.98 min vs 54 ± 0.68 min, P < 0.001) and the total tramadol requirement was higher in TDB Group (490.60 ± 63.09 averagevs. 162.93 ± 63.91 mg, P < 0.001). Intra-and post-operative haemodynamic status was also stable in TDB Group without any adverse event.Conclusion:A TDB patch (10 μg/hour) applied 24 hours before surgery can be used as a postoperative analgesic for lumber fixation surgery without any drug-related adverse effect.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of transdermal buprenorphine patch on post-operative pain relief after elective spinal instrumentation surgery

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Various combinations of gabapentin, ketamine, lidocaine, buprenorphine patch, intrathecal morphine, peripheral nerve block and rectus sheath catheters were used as part of an opioid-sparing strategy. [34][35][36][37][38][39] We avoided sympathetic block with spinal local anaesthetic agent, as it could worsen hypotension during major blood loss. We also avoided using epidural catheters because of the risk of perioperative coagulopathy.…”

Section: Discussionmentioning

confidence: 99%

Anaesthetic challenges for pelvic reconstruction with custom three-dimensional-printed titanium implants: A retrospective cohort study

Chua

Kam

et al. 2019

Anaesth Intensive Care

View full text Add to dashboard Cite

Custom 3D printed titanium implant pelvic reconstructive surgery was implemented as a novel technique at our institutions in the last five years. It provided an option for pelvic bone malignancy patients who were previously deemed unsuitable for re-implantation of irradiated resected bone segments, as well as in revision total hip arthroplasty associated with excessive acetabular bone loss. A retrospective cohort study of the anaesthetic management of patients who underwent pelvic reconstructive surgery using custom 3D printed titanium implants from August 2013 to July 2018 was conducted. Twenty-seven patients were included in the study; 23 patients completed single-stage procedures with a mean (standard deviation) duration of surgery of 7.5 (3.3) hours (median 6.8, range 3.0–15.8 hours), and mean intraoperative blood loss of 5400 (3100) mL (median 6000, range 1400–10,000 mL). Surgery involving the sacrum ( n = 7) was associated with longer intensive care stay, longer total length of hospital stay and, in three cases, unplanned two-stage procedures. The twenty procedures not involving the sacrum were successfully completed in a single stage. The major anaesthetic challenges included massive blood loss, prolonged surgery, interventions to prevent calf compartment syndrome, and perioperative thromboembolism. Preoperative pelvic radiotherapy, malignant tumours, and procedures involving the sacrum were associated with massive intraoperative blood loss and more prolonged surgery.

show abstract

“…To our knowledge, there are no clinical trials of buccal buprenorphine film for acute pain, but transdermal buprenorphine has proven efficacy in the treatment of postsurgical acute pain. [71][72][73][74][75][76] Future studies may provide more information regarding additional uses for buprenorphine in pain management; however, these formulations are not currently FDA approved for acute pain treatment.…”

Section: The Clinical Efficacy Of Buprenorphine In Chronic Painmentioning

confidence: 99%

<p>Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain</p>

Pergolizzi¹,

Raffa²

2019

JPR

View full text Add to dashboard Cite

Background: Chronic pain is associated with decreased quality of life and is one of the most common reasons adults seek medical care, making treatment imperative for many aspects of patient well-being. Chronic pain management typically involves the use of Schedule II full μ-opioid receptor agonists for pain relief; however, the increasing prevalence of opioid addiction is a national crisis that is impacting public health and social and economic welfare. Buprenorphine is a Schedule III partial μ-opioid receptor agonist that is an equally effective but potentially safer treatment option for chronic pain than full μ-opioid receptor agonists. The purpose of this review is to provide an overview of the clinical efficacy and safety of the transdermal and buccal formulations of buprenorphine, which are approved by the Food and Drug Administration for chronic pain, compared with that of extended-release full μ-opioid receptor agonists. Methods: Controlled or randomized controlled clinical trial information was retrieved from EMBASE, Medline, and PubMed using the search terms "buprenorphine" AND "chronic" AND "pain." Results: A total of 33 clinical studies were ultimately used in this review, including 29 (88%) on transdermal buprenorphine and 4 (12%) on buprenorphine buccal film. Although the measure of pain intensity varied among studies, each of these 33 trials demonstrated efficacy for buprenorphine in pain relief. A total of 28 studies also assessed safety, with each concluding that buprenorphine was generally well tolerated. Conclusion: Comparison of current clinical data along with results of responder and safety analyses support the use of buprenorphine over full μ-opioid receptor agonists for effective preferential treatment of chronic pain; however, head-to-head clinical studies are warranted.

show abstract

Transdermal Buprenorphine Patches for Postoperative Pain Control in Abdominal Surgery

Cited by 13 publications

References 16 publications

Efficacy of transdermal buprenorphine patch on post-operative pain relief after elective spinal instrumentation surgery

Efficacy of transdermal buprenorphine patch on post-operative pain relief after elective spinal instrumentation surgery

Anaesthetic challenges for pelvic reconstruction with custom three-dimensional-printed titanium implants: A retrospective cohort study

<p>Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain</p>

Contact Info

Product

Resources

About